Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Lymphocytic Leukemia (CLL): early-phase trial registry
13 of 30 indexed Chronic Lymphocytic Leukemia (CLL) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 13 currently recruiting · #519 of 28,707 conditions by registered trial count
Chronic Lymphocytic Leukemia (CLL): 30 US clinical trials tracked, 13 recruiting.
Chronic Lymphocytic Leukemia (CLL) is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition chronic-lymphocytic-leukemia-cll
OPEN 13 | RECR 43% | LATE 0 | EARLY 24 | RANK #519 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Bronchopulmonary Dysplasia (43% recruiting · 30 trials)
Chronic Lymphocytic Leukemia (CLL) lists 13 open slots (43% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Lymphocytic Leukemia (CLL) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Lymphocytic Leukemia (CLL) is recruiting above its size-band peers.
13 of 30 indexed trials (43.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Chronic Lymphocytic Leukemia (CLL) trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 4 of 30 trials (13.3%). 21 distinct sponsors appear on at least one study for this condition label.
-
Most Chronic Lymphocytic Leukemia (CLL) trials plan to enrol fewer than 100 people.
Median target enrolment is 80 among the 30 trials that report a genuine target (sentinel values excluded). 18 of those (60%) plan for fewer than 100 participants.
-
Chronic Lymphocytic Leukemia (CLL) research is mostly interventional.
25 interventional and 5 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
National Cancer Institute (NCI)
NCT01087333
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics
NCT05131022
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT06788639
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics
NCT04830137
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Memorial Sloan Kettering Cancer Center
NCT03824483
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
National Heart, Lung, and Blood Institute (NHLBI)
NCT05724121
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Umoja Biopharma
NCT06528301
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Medical College of Wisconsin
NCT04186520
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nurix Therapeutics
NCT07221500
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
H. Lee Moffitt Cancer Center and Research Institute
NCT07030400
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
AbbVie
NCT04895436
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Dana-Farber Cancer Institute
NCT05168930
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
National Heart, Lung, and Blood Institute (NHLBI)
NCT07428707
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
Memorial Sloan Kettering Cancer Center
NCT04447768
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
Memorial Sloan Kettering Cancer Center
NCT04419519
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
Dana-Farber Cancer Institute
NCT03580928
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Baylor College of Medicine
NCT00840853
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
NCT03085173
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Bio-Path Holdings
NCT04072458
informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
Pharmacyclics
NCT02582879
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Novartis Pharmaceuticals
NCT01520922
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT02793544
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TG Therapeutics
NCT01647971
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
University of Rochester
NCT03788291
Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
University of Rochester
NCT03771157
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Genzyme, a Sanofi Company
NCT00694590
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Calibr, a division of Scripps Research
NCT04450069
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
Fate Therapeutics
NCT01527838
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Massachusetts General Hospital
NCT01758042
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells
Baylor College of Medicine
NCT00458679
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Lymphocytic Leukemia (CLL) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Lymphocytic Leukemia (CLL) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Lymphocytic Leukemia (CLL) page
30 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Chronic Lymphocytic Leukemia (CLL) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Chronic Lymphocytic Leukemia (CLL) trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Lymphocytic Leukemia (CLL) condition card totals 30 registered trials; most-linked intervention Venetoclax; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.